论文部分内容阅读
目的:利用人/鼠嵌合模型评价人黑色素瘤基因mage-3基因疫苗的免疫效果。方法:建立并鉴定Trimera动物模型,并用重组质粒mage-3/pCI-neo作为基因疫苗对其进行免疫。检测免疫动物脾细胞CTL的杀伤活性和血清中mage-3特异性抗体。结果:构建的Trimera模型脾脏和腹腔中出现了大量的人淋巴细胞。接种后,Trimera模型体内出现了效价为1:256的mage-3特异抗体。免疫动物CTL体外杀伤实验显示,注射基因疫苗的Trimera小鼠脾脏淋巴细胞对靶细胞LB373的最大杀伤率为50%左右,而对照小鼠只有10%以下的杀伤水平。结论:mage-3是一种理想的肿瘤疫苗,在人源化动物模型中能激发出特异的细胞和体液免疫,对共享mage-3抗原的各种肿瘤细胞的临床治疗提供了实验依据。
OBJECTIVE: To assess the immunogenicity of the human melanoma gene mage-3 gene vaccine using a human / mouse chimeric model. Methods: Trimera animal model was established and identified and immunized with the recombinant plasmid mage-3 / pCI-neo as a gene vaccine. The cytotoxic activity of splenocytes from immunized animals and mage-3 specific antibody in serum were detected. Results: A large number of human lymphocytes appeared in the spleen and peritoneal cavity of the constructed Trimera model. After inoculation, the trimera model developed a mage-3 specific antibody with a titer of 1: 256 in vivo. CTL vaccination in vitro showed that the maximum killing rate of spleen lymphocytes of gene-inoculated mice against target cell LB373 was about 50%, while that of control mice was only below 10%. Conclusion: mage-3 is an ideal tumor vaccine that can stimulate specific cellular and humoral immunity in humanized animal models and provide experimental evidence for the clinical treatment of various tumor cells that share mage-3 antigen.